Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial
Acetazolamide and Tubuloglomerular Feedback in Persons With Type 1 Diabetes: A Randomized Crossover Trial
University of California, San Diego
25 participants
Aug 14, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this study is to learn about the effect of the study drug acetazolamide in individuals with Type 1 Diabetes. Specifically, whether acetazolamide provides benefits to the kidneys while minimizing any side effects of the drug. These changes will be measured by laboratory tests that tell us how well the kidneys are functioning.
Eligibility
Inclusion Criteria8
- Males and Females ≥ 18 years at the time of consent.
- Individuals able to become pregnant of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Individuals of child bearing potential must agree to use two methods of contraception during the entire study.
- Individuals able to cause a pregnancy must be willing to use clinically acceptable method of contraception during the entire study.
- Have a clinical diagnosis of Type 1 Diabetes on a stable medication regimen for at least 3 months.
- eGFR (estimated glomerular filtration rate) ≥ 45ml/min/1.73m2
- Serum bicarbonate ≥ 24 meq/L
- Negative urine toxicology screen.
- Able to provide written informed consent approved by an Institutional Review Board (IRB).
Exclusion Criteria12
- History of allergic reaction to acetazolamide, another carbonic anhydrase inhibitor, or any of the inactive ingredients in the acetazolamide tablets.
- Liver disease (clinical diagnosis of cirrhosis by imaging of physician; > 14 drinks/week; AST (Aspartate Transferase), ALT (Alanine Aminotransferase), or total bilirubin > 2 times the upper limit of normal).
- Serum hemoglobin A1c > 10.0%
- Serum hemoglobin concentration of <8 g/dL.
- Use of > 4 anti-hypertensives, or systolic blood pressure >160mm Hg at the screening visit.
- Use of loop, thiazide or potassium sparing diuretics.
- A medical condition requiring active surgical or medical intervention whose urgency would preclude participation in this study at the discretion of the site investigator (active cardiac or pulmonary conditions, ongoing ischemia or cardiac symptoms, uncorrected Coronary Artery Disease (CAD) or decompensated congestive heart failure (CHF)).
- Institutionalized individual (prisoners, patients with signification mental illness, or nursing home residents).
- Active pregnancy, breastfeeding, or planning to become pregnant during the study period.
- Current participation in another clinical trial (observational studies are exempted) trial.
- In the opinion of the investigators, inability to adhere to the study medical regimen or comply with recommendations.
- Inability or unwillingness to travel to study visits.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Acetazolamide is a potent carbonic anhydrase inhibitor that acts on the renal proximal tubule. Through this mechanism, it inhibits proximal tubule sodium reabsorption.
Standard pharmaceutical filler will be capsulated and packaged identically to the acetazolamide.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06981234